BCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
BioCryst Pharmaceuticals Inc (BCRX) is not a strong buy for a beginner investor with a long-term strategy at this time. While the company has shown some revenue growth and has a promising product portfolio, the financial performance is weak, insider selling is significant, and market sentiment remains low. The technical indicators and options data do not suggest a compelling entry point either. For a beginner investor seeking long-term growth, this asset does not currently align with the desired profile.
The MACD is positive and expanding, suggesting mild bullish momentum. However, the RSI is neutral, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading near its pivot point (6.56) with resistance at 6.818 and support at 6.302. Overall, the technical indicators do not suggest a strong buy signal.
Approval of Orladeyo for pediatric patients, which expands its market potential.
Revenue growth of 36.14% YoY in Q3
Acquisition of Astria Therapeutics, adding a new therapy to its portfolio.
Significant insider selling, with a 1842.59% increase in the last month.
Net income dropped by 191.92% YoY, and EPS fell by 185.71% YoY in Q3
Market sentiment is low due to underperformance and lukewarm reactions to recent developments.
Analysts suggest better alternatives in the biotech sector.
In Q3 2025, revenue increased by 36.14% YoY to $159.4M, but net income dropped by 191.92% YoY to $12.9M. EPS also declined by 185.71% YoY to 0.06. Gross margin improved slightly to 98.63%. Overall, while revenue growth is promising, profitability metrics have significantly deteriorated.
Analysts have a Buy rating on the stock, with H.C. Wainwright recently raising the price target from $30 to $32 due to the approval of Orladeyo for pediatric patients. However, market confidence remains low, and other biotech stocks are considered better alternatives.
